Lilly's orforglipron posts Phase 3 diabetes results; six new trials registeredSep 18Weekly roundup, 7 itemsEli Lillyorforglipron
Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial dataSep 4Weekly roundup, 7 itemsEli Lillylasmiditan
Lilly registers four new trials: Alzheimer's, cardiovascular, obesity, Crohn's programsAug 27Weekly roundup, 5 itemsclazakizumabEli Lilly
Lilly posts orforglipron Phase 3 results; adds new early-phase studiesAug 14Weekly roundup, 6 itemsbaricitinibbrenipatide
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growthAug 5Quarterly updateEli Lillytirzepatide
Lilly wins two label supplements: orforglipron tablet and teriparatide solutionAug 4Weekly roundup, 2 itemsEli Lillyorforglipron
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 resultsJul 30Quarterly updateMadrigal Pharmaceuticals, Inc.resmetirom
Lilly completes Phase 3 ATTAIN-J trial of oral orforglipron in Japanese obesity patientsJul 20Trial updateEli Lillyorforglipron
Lilly posts results for five completed Phase 1 studies, opens three new early trialsJul 17Weekly roundup, 8 itemsEli Lillyeloralintide
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Lilly posts ACHIEVE-J results; Olumiant, Strattera labels updatedJul 2Weekly roundup, 5 itemsabemaciclibbaricitinib
Sign inSign in